IBA H1 2025 slides: revenue jumps 40%, maintains full-year guidance despite challenges

Ion Beam Applications SA (IBA) reported a robust 40% year-over-year revenue increase to €304.9 million for H1 2025, driven by accelerating equipment backlog conversion, particularly a 137% surge in Proton Therapy equipment sales and strong performance from IBA Technologies. Despite a €2.6 million net loss, the company achieved a recurring operating profit (REBIT) of €10.6 million and significantly improved its net debt position, reaffirming its full-year REBIT guidance of over €25 million. While shares edged down 1.67% post-announcement, IBA maintained its market leadership in proton therapy and is implementing mitigation strategies for challenges like US tariffs and China procurement restrictions, with management expressing optimism for continued growth and profitability improvements into 2028.

Analysis

Ion Beam Applications SA (IBAB) demonstrated significant operational acceleration in its H1 2025 results, with revenue surging 40% year-over-year to €304.9 million. This growth was primarily fueled by the conversion of its equipment backlog, highlighted by a 137% increase in Proton Therapy (PT) equipment sales. Despite this top-line strength and an improvement in recurring operating profit (REBIT) to €10.6 million from breakeven, the company recorded a net loss of €2.6 million, though this was a €7.7 million improvement from H1 2024. The company's financial health strengthened, with net debt reduced to €30 million from €63 million. Segment performance was mixed; IBA Technologies was the key profit driver with an 82% REBIT surge and an 11.3% margin, while the core Proton Therapy unit, despite 55% revenue growth, remained in a loss-making position with a REBIT of -€2.2 million. Management reaffirmed its full-year 2025 guidance for REBIT to exceed €25 million, signaling confidence in a stronger second half. While facing headwinds from US tariffs and Chinese procurement restrictions, the company has outlined specific mitigation strategies and quantified the financial impact as marginal. IBA maintains a dominant 41% market share in installed proton therapy rooms, and a cited PEG ratio of 0.19 suggests its growth trajectory may be undervalued.

Key Decisions for Investors

• Given the strong 40% revenue growth, improving profitability, and reaffirmed full-year guidance, the 1.67% stock decline could present a dislocation for investors to consider accumulating a position based on operational momentum.
• Investors should closely monitor the profitability of the Proton Therapy segment, as its successful turnaround to positive REBIT is critical for achieving the company's medium-term target of a 10% operating margin by 2028.
• Pay close attention to the company's execution on its mitigation strategies for US tariffs and Chinese market access, as any deviation from the currently projected marginal impact could affect future order intake and profitability.